Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jaume Puig-Junoy, Natàlia Pascual-Argente, Lluc Puig-Codina, Laura Planellas & Míriam Solozabal. (2018) Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Review of Gastroenterology & Hepatology 12:12, pages 1251-1263.
Read now
Read now
Giovanni Cenderello, Stefania Artioli, Claudio Viscoli, Ambra Pasa, Mauro Giacomini, Barbara Giannini, Chiara Dentone, Laura Ambra Nicolini, Giovanni Cassola & Antonio Di Biagio. (2016) Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. ClinicoEconomics and Outcomes Research 8, pages 15-21.
Read now
Read now
Vincenzo Boccaccio, Maria Luisa Russo, Marco Carbone & Savino Bruno. (2015) Treatment discontinuation with peg-interferon: what to consider. Expert Review of Clinical Pharmacology 8:6, pages 761-768.
Read now
Read now
Articles from other publishers (12)
R. A. Yakhina, I. A. Lakman, D. A. Valishin & R. Kh. Bakhitova. (2022) Economic burden of chronic viral hepatitis C. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 14:4, pages 523-536.
Crossref
Crossref
Ru Han, Clément François & Mondher Toumi. (2020) Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results. Applied Health Economics and Health Policy 19:1, pages 29-44.
Crossref
Crossref
László Szilberhorn, Zoltán Kaló & Tamás Ágh. (2018) Cost-Effectiveness of Second-generation Direct-acting Antiviral Agents in Chronic HCV Infection: A Systematic Literature Review. Antiviral Therapy 24:4, pages 247-259.
Crossref
Crossref
Rodolfo Castro, Louise Crathorne, Hugo Perazzo, Julio Silva, Chris Cooper, Jo Varley-Campbell, Daniel Savignon Marinho, Marcela Haasova, Valdilea G. Veloso, Rob Anderson & Chris Hyde. (2018) Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Medical Research Methodology 18:1.
Crossref
Crossref
Lauren E. Cipriano & Jeremy D. Goldhaber-Fiebert. (2018) Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy & Practice 3:1, pages 238146831877663.
Crossref
Crossref
X. Li, N. S. Chan, A. W. Tam, I. F. N. Hung & E. W. Chan. (2017) Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. European Journal of Clinical Microbiology & Infectious Diseases 36:10, pages 1801-1809.
Crossref
Crossref
Andrew J. Leidner, Harrell W. Chesson, Philip R. Spradling & Scott D. Holmberg. (2016) Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Applied Health Economics and Health Policy 15:1, pages 65-74.
Crossref
Crossref
Roberto Nuño Solinís, Patricia Arratibel Ugarte, Ander Rojo & Yuri Sanchez Gonzalez. (2016) Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infectious Diseases and Therapy 5:4, pages 491-508.
Crossref
Crossref
Miriam Luhnen, Siw Waffenschmidt, Andreas Gerber-Grote & Gloria Hanke. (2016) Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review. Applied Health Economics and Health Policy 14:5, pages 527-543.
Crossref
Crossref
Winnie de Bruijn, Cristina Ibáñez, Pia Frisk, Hanne Bak Pedersen, Ali Alkan, Patricia Vella Bonanno, Ljiljana S. Brkičić, Anna Bucsics, Guillaume Dedet, Jaran Eriksen, Joseph O. Fadare, Jurij Fürst, Gisselle Gallego, Isabella P. Godói, Augusto A. Guerra Júnior, Hakkı Gürsöz, Saira Jan, Jan Jones, Roberta Joppi, Saim Kerman, Ott Laius, Newman Madzikwa, Einar Magnússon, Mojca Maticic, Vanda Markovic-Pekovic, Amos Massele, Olayinka Ogunleye, Aisling O'Leary, Jutta Piessnegger, Catherine Sermet, Steven Simoens, Celda Tiroyakgosi, Ilse Truter, Magnus Thyberg, Kristina Tomekova, Magdalena Wladysiuk, Sotiris Vandoros, Elif H. Vural, Corinne Zara & Brian Godman. (2016) Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Frontiers in Pharmacology 7.
Crossref
Crossref
Jagpreet Chhatwal, Tianhua He & Maria A. Lopez-Olivo. (2016) Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. PharmacoEconomics 34:6, pages 551-567.
Crossref
Crossref
Rujipat Wasitthankasem, Nawarat Posuwan, Preeyaporn Vichaiwattana, Apiradee Theamboonlers, Sirapa Klinfueng, Viboonsak Vuthitanachot, Napha Thanetkongtong, Siriporn Saelao, Monthana Foonoi, Apinya Fakthongyoo, Jamorn Makaroon, Klaita Srisingh, Duangporn Asawarachun, Somchai Owatanapanich, Norra Wutthiratkowit, Kraisorn Tohtubtiang, Pornsak Yoocharoen, Sompong Vongpunsawad & Yong Poovorawan. (2016) Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey. PLOS ONE 11:2, pages e0149362.
Crossref
Crossref